Skip to main content
SpringerLink
Log in

Monotherapy Versus Combination Therapy in the Prevention of Hepatitis B in Liver Transplant Recipients

  • Current Opinion
  • Published:
BioDrugs Aims and scope Submit manuscript

Abstract

Tremendous progress with liver transplantation for hepatitis B-related liver disease has occurred over the past decade, primarily through advances in antiviral therapy. In the most recent clinical trials, reinfection of the transplanted allograft with host hepatitis B virus has been shown to be rare, even in patients with evidence of viral replication at the time of liver transplantation. The elimination of recurrent infection has allowed centres to investigate more cost-effective protocols. However, additional research, both clinical and basic, is needed to prevent the emergence of drug-resistant infections.

This article compares the current protocols for the prevention of recurrent infection with reference to the worldwide experience of liver transplantation for hepatitis B over the last 30 years. Nonviraemic patients (positive for hepatitis B surface antigen only) can receive a liver transplant with a low risk of recurrent infection using lamivudine alone, hepatitis B immunoglobulin (HBIG) alone or HBIG and lamivudine in combination. Viraemic patients (positive for either hepatitis B e antigen or viral DNA) should receive treatment exclusively with HBIG plus lamivudine. A pretransplant course of lamivudine may not be necessary in either group of patients, and it poses the additional risk of the emergence of a YMDD mutant infection prior to transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torisu M, Yokoyama T, Amemiya H, et al. Immunosuppression, liver injury, and hepatitis in renal, hepatic, and cardiac homograft recipients: with particular reference to the Australia antigen. Ann Surg 1971; 174 (4): 621–39

    Article  Google Scholar 

  2. Johnson PJ, Wansbrough-Jones MH, Portman B, et al. Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. BMJ 1978; 1 (6107): 216

    Article  PubMed  CAS  Google Scholar 

  3. Macdougall BR, Johnson PJ, Williams R, et al. Liver transplantation in a 27-year-old female with familial HBsAg-positive hepatocellular carcinoma. Neth J Med 1978; 21 (3): 101–16

    PubMed  CAS  Google Scholar 

  4. Portmann B, O’Grady J, Williams R. Disease recurrence following orthotopic liver transplantation. Transplant Proc 1986; 18: 136–41

    Google Scholar 

  5. Lauchart W, Muller R, Pichlmayr R. Immunoprophylaxis of HBV reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 2387–9

    PubMed  CAS  Google Scholar 

  6. Lauchart W, Muller R, Pichlmayr R. Long-term Immunoprophylaxis of HBV reinfection in recipients of human liver allografts. Transplant Proc 1987; 19: 4051–3

    PubMed  CAS  Google Scholar 

  7. Muller R, Lauchart W, Farle M, et al. Simultaneous passive-active immunization for preventing HBV reinfection in hepatitis B surface antigen-positive liver transplant recipients. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, Inc., 1988; 810–2

    Google Scholar 

  8. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842–7

    Article  PubMed  CAS  Google Scholar 

  9. Gugenheim J, Crafa P, Fabiani P, et al. Long-term passive immunoprophylaxis of B virus recurrence after liver transplantation in HBS antigen-positive patients. Transplant Proc 1993; 25: 1349–50

    PubMed  CAS  Google Scholar 

  10. Samuel D, Zignego A, Reynes M, et al. Long-term and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 1995; 21: 333–9

    Article  PubMed  CAS  Google Scholar 

  11. Grazi LG, Mazziotti A, Sama C, et al. Liver transplantation in HBsAg-positive HBV-DNA-negative cirrhotics: immunoprophylaxis and long-term outcome. Liver Transpl Surg 1996; 2: 418–25

    Article  PubMed  CAS  Google Scholar 

  12. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358–64

    Article  PubMed  CAS  Google Scholar 

  13. Sawyer RG, McGory RW, Gaffey MJ, et al. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 1998; 227: 841–50

    Article  PubMed  CAS  Google Scholar 

  14. Fung JJ, Ostberg L, Shapiro R, et al. Human monoclonal antibody against hepatitis B surface antigen in preventing recurrent hepatitis B following liver transplantation. In: Hollinger F, Lemon S, Margolis H, editors. Viral hepatitis and liver disease. Baltimore (MD): Williams & Wilkins, 1991; 651

    Google Scholar 

  15. McMahon G, Ehrlich PH, Moustafa ZA, et al. Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBsAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992; 15: 757–66

    Article  PubMed  CAS  Google Scholar 

  16. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348 (9036): 1212–5

    Article  PubMed  CAS  Google Scholar 

  17. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996; 62 (10): 1456–62

    Article  PubMed  CAS  Google Scholar 

  18. Perillo RP, Schiff ER, Dienstag JL, et al. Lamivudine for prevention of recurrent hepatitis B after liver transplantation: final results of a U.S./Canadian multicenter trial [abstract no. 245]. Hepatology 1999; 30: 222A

    Article  Google Scholar 

  19. Ling R, Mutimer DJ, Ahmed M, et al. Selection of mutations in the HBV polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711–3

    Article  PubMed  CAS  Google Scholar 

  20. Tipples GA, Ma MM, Fischer KP, et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714–7

    PubMed  CAS  Google Scholar 

  21. Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine following hepatitis immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434–9

    Article  PubMed  CAS  Google Scholar 

  22. Nery J, Berho M, Nery-Avila C, et al. Lamivudine monotherapy in non-viremic HBsAg+ liver transplant recipients [abstract no. 196]. Liver Transpl 2000; 6: C–49

    Google Scholar 

  23. Balan V, Dodson FS, Vargas HE, et al. Long term follow-up of lamivudine therapy for hepatitis B before and after liver transplantation: clinical implication of development of the YMDD mutant [abstract no. 741]. Hepatology 1999; 30: 346A

    Google Scholar 

  24. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis immune globulin. Hepatology 1998; 28: 585–9

    Article  PubMed  CAS  Google Scholar 

  25. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491–6

    Article  PubMed  CAS  Google Scholar 

  26. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for HBV precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis immune globulin. Liver Transpl Surg 1999; 5: 512–9

    Article  PubMed  CAS  Google Scholar 

  27. Yoshida EM, Siegfried RE, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520–5

    Article  PubMed  CAS  Google Scholar 

  28. Angus PW, McCaughan GW, Gane EJ, et al. Combination low dose hepatitis immune globulin (HBIG) and lamivudine therapy provides effective prophylaxis against posttransplantion hepatitis B. Liver Transpl 2000; 6: 429–33

    Article  PubMed  CAS  Google Scholar 

  29. Dodson SF, Issa S, Bonham A. Liver Transplantation for chronic viral hepatitis. Surg Clin North Am 1999; 79: 131–45

    Article  PubMed  CAS  Google Scholar 

  30. Dodson SF, Shakil O, Bonham A, et al. HBIG and lamivudine after liver transplantation for hepatitis B related liver disease [abstract 767]. Transplantation 2000; 69: S312

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thomas E. Starzl Transplantation Institute, Pittsburgh, Pennsylvania, USA

    S. Forrest Dodson

Authors
  1. S. Forrest Dodson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Forrest Dodson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dodson, S.F. Monotherapy Versus Combination Therapy in the Prevention of Hepatitis B in Liver Transplant Recipients. BioDrugs 14, 205–209 (2000). https://doi.org/10.2165/00063030-200014040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00063030-200014040-00001

Keywords

Search

Navigation